key: cord-0896283-qxz3x4kc authors: Paul, Abhik; Sarkar, Arnab; Saha, Sanjukta; Maji, Avik; Janah, Pritha; Kumar Maity, Tapan title: Synthetic and computational efforts towards the development of peptidomimetics and small-molecule SARS-CoV 3CLpro inhibitors: a review date: 2021-07-03 journal: Bioorg Med Chem DOI: 10.1016/j.bmc.2021.116301 sha: 30361a720c2896a89f60f608bf644f37828cba65 doc_id: 896283 cord_uid: qxz3x4kc Severe Acute Respiratory Syndrome (SARS) is a severe febrile respiratory disease caused by the beta genus of human coronavirus, known as SARS-CoV. Last year, 2019-n-CoV (COVID-19) was a global threat for everyone caused by the outbreak of SARS-CoV-2. 3CLpro, chymotrypsin-like protease, is a major cysteine protease that substantially contributes throughout the viral life cycle of SARS-CoV and SARS-CoV-2. It is a prospective target for the development of SARS-CoV inhibitors by applying a repurposing strategy. This review focuses on a detailed overview of the chemical synthesis and computational chemistry perspectives of peptidomimetic inhibitors (PIs) and small-molecule inhibitors (SMIs) targeting viral proteinase discovered from 2004-2020. The PIs and SMIs are one of the primary therapeutic inventions for SARS-CoV. The journey of different analogues towards the evolution of SARS-CoV 3CLpro inhibitors and complete synthetic preparation of nineteen derivatives of PIs and ten derivatives of SMIs and their computational chemistry perspectives were reviewed. From each class of derivatives, we have identified and highlighted the most compelling PIs and SMIs for SARS-CoV 3CLpro. The protein-ligand interaction of 29 inhibitors were also studied that involved with the 3CLpro inhibition, and the frequent amino acid residues of the protease were also analyzed that are responsible for the interactions with the inhibitors. This work will provide an initiative to encourage further research for the development of effective and drug-like 3CLpro inhibitors against coronaviruses in the near future. Severe Acute Respiratory Syndrome (SARS) is a severe febrile respiratory disease caused by the beta genus of human coronavirus, known as SARS-CoV. Last year, 2019-n-CoV (COVID- 19 ) was a global threat for everyone caused by the outbreak of SARS-CoV-2. 3CLpro, chymotrypsin-like protease, is a major cysteine protease that substantially contributes inhibitors were also studied that involved with the 3CLpro inhibition, and the frequent amino acid residues of the protease were also analyzed that are responsible for the interactions with the inhibitors. This work will provide an initiative to encourage further research for the development of effective and drug-like 3CLpro inhibitors against coronaviruses in the near future. In November 2002, Severe Acute Respiratory Syndrome (SARS) was first identified in Guangdong Province of Southern China and immediately within a few months was considered to be a global threat because of its highly contagious and deadly nature. From November 2002 to 2003, it spread rapidly over 29 countries. Total 8439 cases were reported globally till 3rd July 2003, and among which 812 patients died 1,2 . The etiological agent solely responsible for this SARS was found to be a novel human coronavirus called SARS-CoV. Some changes in the phylogenetic characters and gene sequence of SARS-CoV distinguish it from other previously discovered 3, 4 SARS is characterized by fever, and after a few days, it is followed by shortness of breath and dry nonproductive cough, headache, dyspnea, lower respiratory tract infection, lymphopenia, and diarrhoea 5 . Coronaviruses are enveloped, positive-stranded RNA virus and belong to order Nidovirales, family Coronaviridae, sub-family Coronavirinae genus Coronavirus. Genus is of four types alpha, beta, gamma, and delta Coronavirus. The beta coronavirus with "b" lineage is mainly responsible for SARS-CoV disease 3, 6 . The schematic representation of the taxonomy is described in Figure 1 . Coronaviruses are zoonotic viruses, primarily originated from non-humans (animal reservoirs, especially bats and avian species) and then transmitted to humans 7 cases were reported with 574 deaths (fatality rate -38%) 8, 9 . The disease caused by SARS-CoV-2, also known as coronavirus disease , as the first case was reported in Wuhan, China, in December 2019. COVID-19 has been declared a worldwide pandemic by World Health Organization (WHO) on March 11, 2020 . Till the mid of August 2020, 21.2 million cases were reported, including 76100 deaths 10, 11 . Even though the death rate is lower than SARS-CoV, the infection rate is quite high, so SARS-CoV-2 is considered a severe medical emergency. In recent times, several pharmaceutical companies successfully developed vaccines to treat COVID-19, but no specific anti-viral drugs have been discovered. Chymotrypsin-like cysteine protease (3CLpro) is the major protease involved in viral replication of SARS-CoV, and it has also been found that the sequence similarity between SARS-CoV and SARS-CoV-2 is 96% 5, 8 . By targeting this protease enzyme, many researchers have designed and developed potential inhibitors against coronaviruses. The potential SARS-CoV 3CLpro inhibitors have a particular parent moiety that can be modified structurally to develop a new effective drug. The most advanced pre-clinical therapeutic drugs for SARS-CoV-2 3CLpro are PF-00835231, PF-07304814, GC-376, and PF-07321332 (Figure 2) 12, 13 . Based on the identical sequence similarity between SARS-CoV and SARS-CoV-2, the inventors of PF-0083523 have recently developed a new covalent inhibitor for treating COVID-19 14 . Another potent and selective SMI against SARS-CoV-2 3CLpro is ALG-097111 which was evaluated in the COVID-19 infected Syrian Hamster Model for antiviral activity 15 . To combat the current outbreak of COVID-19, the scientific community is trying to develop effective treatment within a feasible time. Many well-established strategies are taken by the research organizations to eradicate the COVID-19 pandemic 16, 17 . In the field of drug discovery and development, repurposing of existing drugs is one of the organized and economic strategies to fight against novel diseases, like novel coronavirus 18 . The bioinformatics and pharmacoinformatic approaches have played a massive role in repurposing the existing drugs. By this strategy, many scientific workers have generated and identified numerous newer inhibitors against target diseases 19 . In the battle of COVID-19, the anti-SARS-CoV compounds are mostly explored and repurposed for screening the best-fit inhibitors 6 . With the help of computational chemistry, recently, Bhowmik and their collaborators identified Nafamostat and VR23 as promising candidates for treating COVID-19 by targeting SARS-CoV-2 3CLpro (Figure 2) . The pharmacodynamic study revealed that the Nafamostat and VR23 are promising for drug-likeness but further pre-clinical/clinical investigation studies are needed to be procured for understanding the efficacy and potency of the compounds 20 . Apart from the pharmacoinformatic approaches, chemical synthesis is an integral part of drug discovery and development; to synthesize the novel molecules for the target diseases 21 . Since now, many organic chemists have explored and discovered the different types of novel inhibitors targeting the SARS-CoV 3CLpro, such as peptidomimetic inhibitors (PIs), small-molecule inhibitors (SMIs), and metal conjugate inhibitors. Researchers can't evaluate the in vitro or in vivo efficacy and potency of inhibitors without the chemical synthesis of designed inhibitors. So, wet lab chemical synthesis has always a great interest for researchers in the pharmaceutical industry and scientific field to develop novel chemical entities as a drug 22 . Considering the global pandemic of COVID-19, this review focuses on the chemical synthesis and computational chemistry perspectives of SARS-CoV 3CLpro inhibitors, specially PIs and SMIs, which has been discovered by applying chemical synthesis, in vitro biological assay, and computational chemistry from 2004-2020. inhibitors is provided in Figure 3 . Here, we have classified the SARS-CoV 3CLpro inhibitors into two categories: 1) Peptidomimetic inhibitors (PIs), and 2) Smallmolecule inhibitors (SMIs). The PIs consist of different analogues, including: Keto-Glutamine analogues 23 , Anilide analogues 24 , Peptidomimetic α,ß-unsaturated esters 25 , Glutamic acid and glutamine peptides 26 , Peptidomimetic (TG-0205221) 27 , Phthalhydrazide peptide analogues 28 , Cinanserin analogues 29 , Trifluoromethyl ketone containing peptides 30 , Trifluoromethyl, benzothiazolyl or thiazolyl ketone containing peptidomimetics 31 , Michael type of peptidomimetics 32 , Cysteine protease inhibitors 33 , Potent dipeptide type of peptidomimetics 34 , Novel dipeptide type of peptidomimetics 35 , Nitrile based peptidomimetics 36 , Tripeptide type of peptidomimetics 37 , Peptidomimetics containing cinnamoyl warhead 38 , Peptidomimetics containing decahydroisoquinolin moiety 39 , Ketone-based covalent inhibitors 14 , and α-Ketoamide derivatives 40 . The SMIs are classified into: isatin derivatives 41 , Chloropyridyl ester derivatives 42 , pyrazolone derivatives 43 , pyrimidine derivatives 44 , macrocyclic inhibitors 45 , 5-sulphonyl isatin derivatives 46 , pyrazolone derivatives 47 , serine derivatives 48 , phenylisoserine derivatives 49 , and Octahydroisochromene derivatives 50 . We have also identified the most promising anti-SARS compounds from each class of derivatives and highlighted their structural features and binding information. This work, chemical synthesis, and computational chemistry aspect of SARS-CoV 3CLpro inhibitors will provide an initiative to encourage further research to the organic chemist and medicinal chemists for the design and synthesis of new 3CLpro inhibitors effective against coronaviruses in coming years. Coronaviruses are positive polarity family of polyadenylated single-stranded RNA. In several animal species, even human beings, this virus can cause acute and chronic pulmonary and nervous system diseases 51 . Coronavirus virions feature the largest viral genomes ranging from 27 to 31 kb long found to date. The genome is helically encapsidated by nucleocapsid (N) proteins 52 . Virus cores are formed by the matrix proteins that surround the filamentous nucleocapsid. The virus membrane includes various spike-like protuberances called spike (S) proteins, a type of glycoprotein I along with membrane protein (M) that covers the membrane, and a hydrophobic protein called envelope protein (E) that surrounds the entire virus structure 53 . These proteins make a crown-like appearance, hence the justification of the name Corona, which is derived from a Latin word, while seen in an electron microscope. S proteins act as a protein that binds with the receptor of the host and is a fusion of the viral and cellular membranes 54, 55 . The schematic figure is given in Figure 4 . The SARS-CoV genome consists of two open reading frames bound by a ribosomal frameshift that encodes two overlapping polyproteins, pp1a (approximately 450 kDa) and pp1ab (approximately 750 kDa), that helps to moderate the mechanism of viral replication and transcription. Complex proteolytic processing is involved in the maturation of coronavirus that controls viral gene expression and replication 56 . Some viruses from the same family make use of three proteases in the proteolytic process. In comparison, it is known to encode only two proteases in the case of SARS-CoV. Other than 3CLpro, it also has papain-like cysteine protease (PLpro). 3CLpro, also known as the Main Protease (Mpro), plays a crucial role in the mechanism of viral replication and infection, allowing this macromolecule a prime candidate for antiviral therapy (PDB ID: 1UJ1) 6 Therapeutic interactions between two proteins or protein-protein interactions (PPIs) have been essential in drug design in recent times against various diseases, including metabolic disorders, cancer, neurodegenerative disorders, and several other illnesses. It also has a significant role in various biological processes, including cell proliferation, signal transduction, and apoptosis 60 . Peptidomimetics are molecules whose basic elements in 3D space resemble a standard peptide or protein, which maintain the capability to interact and create the same therapeutic effect with the biological target. Peptidomimetics are intended to overcome some of the complications associated with a native peptide, including proteolysis that affects the duration or half-life of the protein and low bioavailability. Other such properties may also be significantly improved, which includes receptor specificity and efficacy. Thus, in drug development, peptidomimetics have enormous potential. The peptidomimetic design method begins with developing the relationships between structure and activity, also known as SAR that can describe the biological effect 61, 62 . There are various instances of PPI-targeting peptides and peptidomimetics that's been in clinical trials. For example, the first potent and specific p53 re-activator, an important tumor suppressor protein that binds and acts as an inhibitor of two p53 suppressor proteins, namely MDM2 and MDMX, is Aileron (ALRN-6924). p53 is one of the most favoured targets of antineoplastic drugs activated by its vital role in stopping multiple cancers from initiating and advancing 63 . KAI Pharmaceuticals developed a small peptide named KAI-9803, which directly acts as dPKC inhibitor with its intracellular receptor, RACK. During reperfusion, dPKC activation initiates molecular pathways for cell death, which gradually leads to inflammation and injury during a stroke in the heart or brain. In phase II clinical trial to determine safety and effectiveness, KAI-9803 was evaluated for its efficacy in acute myocardial infarction patients 64 . The chemical synthesis of PIs under Keto-Glutamine analogues 23 The synthetic route of a tetrapeptide, Scheme 1A initiated according to the previously reported literature [65] [66] [67] to produced 4a-c. After that, it reacts with trifluoracetic acid for removal of the Boc group. Simultaneously, tripeptide Ac-Val-Thr(OBn)-Leu-OH was added in the reaction medium of DMF to generate tetrapeptide 5a-b. In Scheme 1A, the 5a and 5b compounds were reacted with respective reagents under specific reaction conditions to generate compounds 5c and 5d as shown in Scheme 1B, the 9a and 9b compounds were reacted with appropriate reagents under specific reaction conditions to get another 9c and 9d compounds 67, 68 . Another compound 11 was synthesized without the ketophthalhydrazide group to analyze the effect of tetrapeptide moiety in the compound 9a-d, as shown in Scheme 1C. In-silico studies of the inhibitor 9b revealed that the pyrrolidine-2-one of S1 site interacted with His163 and nitro group of 5-nitro-2,3-dihydrophthalazine-1,4-dione of S2 site interacted with Asn142 residue of the protease (Figure 8) . From all synthesized molecules, 9b has been found the most potent reversible inhibitors against SARS-CoV 3CLpro with IC 50 value 0.6 µM (Figure 8 ) 23 . Figure 7 : Keto-glutamine peptides as a potent inhibitor of HAV 3C-pro. A multiple series of peptide anilides were developed by Shie and co-workers in 2005 based on antihelmintic drug (Niclosamide) 69 and evaluated the anti-SARS activity targeting the 3CLpro enzyme 24 Phe-Phe dipeptides α,ß-unsaturated ester. Then, with compound Phe-Phe dipeptides α,ß-unsaturated ester, several α,β-unsaturated carboxylic acid were reacted to produce a series of analogues (Scheme 3, 3C). Before isolating the compounds, they have done an enzymatic assay and found that the compound 38c was the most potent inhibitor against SARS-CoV 3CLpro enzyme ( Figure 8 ). Molecular modelling study reveals that, out of four series of compounds, the compounds of series 3 and 4 showed better inhibitory results than the compounds of 1 and 2 series against SARS-CoV 3CLpro enzyme. The in-silico study of compound 38c indicates that the (dimethylamino)cinnamyl group of S1 site was occupied by Glu166, Gln189, and Gln192 residues via hydrogen bonding (Figure 8 ) 25 . It has been established that glutamic acid and glutamine peptides with trifluoromethyl ketone groups show good inhibitory activity against the 3CLpro of SARS-CoV. Sydnes and co-workers synthesized a new series of tri-and tetraglutamic acid and glutamine peptide and evaluated against 3CLpro inhibitory activity using a fluorescence-based peptide cleavage assay 26 26 . TG-0205221 is a synthetic compound designed and synthesized by the scientists Syaulan Yang and their research group in 2006 27 . The compound was compared with one natural peptide substrate and it was found that the natural compound showed moderate inhibition against the 3Cpro enzyme but a lower inhibitory activity against 3CLpro of SARS-CoV. Also, from the crystal structure of the drug-receptor complex, it was established that TG-0205221 binds firmly with the 3CLpro enzyme with extensive hydrophobic contact and involves ten hydrophobic bonds and one covalent bond. The compound TG-0205221 (69) was synthesized by a multi-step organic reaction showed in Scheme 5 and The result obtained from the in-silico study of compound 83a showed that the pyridine ring in the S1 site of the compound interacted with the Phe140, Leu141, Asn142, Glu166, His172, His163 amino acid residue and that of the keto group of S2 site interacted with the Ser144, Gly143, Cys145 amino acid residue of the protease (Figure 8 ) 28 . Cinanserin is a 5-HT receptor antagonist which was discovered in the 1960s and The hydrophobic interaction atom pairs between the compound 108a and the enzyme were detected by using the LIGPLOT and it was evident that the benzyl group of S1, S4, S5 positions interacts with Thr25, Leu27, Gly143 (S1); Gln189, Met165, Cys145, Glu166 (S2); and HIs163, Phe140 (S3) respectively. The unsaturated alkyl chain of S2 and S3 sites was found interacting with His41 and Met49 amino acid residues (Figure 8 ) 29 . In 2008, Shao and co-workers designed and synthesized a series of trifluoromethyl ketones (TFMKs) targeting the 3CLpro for SARS-CoV 30 From the computational studies, the interaction between inhibitor 113c and enzyme was studied. The interaction result showed that the benzyl group of S1 site interacting with Met165, Met49, His41, and Cbz-Ala of S2 site interacted with Gln189 amino acid residue. The cbz group of S3 site and alanine of S4 site interacting with amino acid residues, such as Pro168 (S3) and Glu166 (S4). Similarly, amino acid His163 and Phe140 were associated with leucine of S5 site; and keto group of S6 was also found to interact with amino acid residues Gly143 and Cys145 (Figure 8 ) 30 . In 2006, Cai and co-workers reported moderate activity of trifluoromethyl ketone containing peptides against SARS-CoV 3CLpro. It was observed that the moderate inhibitory activity of the compounds was due to cyclization of the compounds, which decreases its interaction with the active site of the SARS-CoV 3CLpro 81 The compounds 125a-f were synthesized in four steps. In the first step, the compound 120 was converted to amides 121 and then reacted with thiazole or benzothiazole in the presence of n-Butyllithium to get compounds 122a-b. In the next step, treatment with formic acid compounds 122a-b produces the compounds 123a-b and further converted into 124a-e by using substituted amines under appropriate reaction conditions. In the last step, the final compounds 125a-f were formed by reacting the compounds 124a-e with peptide molecule under appropriate reaction conditions (Scheme 9, 9B) 82 . The compound 132 was synthesized following the previously published literature via multi-step process 68 . In the first step, the compound 127 was prepared from previous literature methods 68 Protease inhibition assay was carried out on R188I mutant protease by simultaneous addition of both inhibitor and substrate to determine IC 50 value. The result of the experiment suggested that the peptide aldehyde is a competitive inhibitor of SARS 3CLpro because there was no evidence in the formation of a stable covalent bond between inhibitor and protease. In literature, structural optimization following X-ray crystallographic analysis of inhibitor-protease complex gives a potent tetrapeptide aldehyde with Peptide aldehyde 149(a-f) was synthesized by using conventional Weinreb amide resin (Scheme 10, 10B) 84 . The conventional Fmoc-based solidphase synthesis was used to introduce amino acid residues. After peptide chain construction, the resin was reduced with LiAlH 4 to obtain desired compounds. The synthesis of structurally optimized and potent peptide aldehyde is given in Scheme 10, 10C. The synthesis was started with commercially Prior et al designed and synthesized few transition state inhibitors in 2013. They designed these inhibitors of 3CLpro such that it contains a tripeptidyl group and warheads that include aldehyde, bisulfite adduct, a-ketoamide, or an alphahydroxy phosphonate transition state mimic 33 . The glutamine surrogate at the P1 site is essential for recognition because of its compatibility with the substrate specificity for the targeted enzyme. The presence of leucine and arylalanine at the P2 and P3 site enhances the recognition and cell penetrability, respectively. They synthesized the tripeptidyl aldehyde from the starting material glutamine surrogate in five sequential steps, as shown in Scheme 11: 11A and 11B 33 . The FRET based assay and enzyme-based assay were conducted to evaluate the inhibitory activity of these compounds against SARS-CoV 3CLpro 85, 86 . The To develop a low molecular weight compound with 3CLpro inhibitory activity, In search of novel low molecular weight SARS-CoV 3CLpro inhibitors In silico studies revealed that the -NH group of the methoxy aniline, the ketone group and the -NH of pyrolidin-2-one comprising the S1 is found to interact with the Glu166 residue. The -NH group of S2 and S3 interacted with Gln189 and His164 residues, respectively. The carbonyl moiety of S4 position interacted with Ser144 and Cys145. In contrast, the pyrolidin-2-one moiety was found to interact with His163 residue of the protease (Figure 8 ) 35 . In The cyano group of the S1 site was found to interact with the Glu166, Phe140 residues. The amide group of S2 interacted with Cys145. Leu167 was found to interact with the dimethyl group of S3, the amide groups of S4 forms interaction with Thr190, Gln189 and the S5 site comprising the benzyl group interacted with Pro168 of the protease (Figure 8 ) 36 . With an aim to develop novel peptidomimetics as inhibitors of SARS-CoV 3CLpro, Kanno et al designed a series of tripeptide-type compounds containing 4,5-dimethyl thiazole, 5-methyl thiazole, bezothiazole, and a series of 5arylated thiazole at P1′ position, other substituents at P2 and P4 positions were also rigorously optimized to achieve the best fit for protease inhibition activity. The initial molecular modelling study involving a thiazolyl ketone-containing The dimethyl aniline group of the S1 site was found to interact with the Ala191 residue. The -NH group and the ketone of S2 interlinked with Glu166. Glu189, His41 residues were found to interact with the amide group of S3, the benzothiazole groups of S4 formed interaction with Cys145, Ser144 and Gly143 and the S5 site comprising the dimethyl group interacted with His163 of the protease (Figure 8) 37 . In The result obtained from the in silico study of compound 256 showed that the pyridine ring in the S1 site of the compound interacted with the Cys145 amino acid residue and that of the carbonyl group of S2 site interacted with the Cys145, Gly143, amino acid residues of the protease (Figure 8) 14 . Zhang et al in their research work, developed broad-spectrum antivirals against enterovirus, alpha coronavirus, and beta coronavirus. Because the protease of these virus shares a common active site architecture and an unique specificity for substrate recognition, they pursued a structure-based design of peptidomimetic α-ketoamides near equipotent against the three virus genera. The proteases targeted in this study specifically cleave peptide following glutamine residue in the P1 position, they have incorporated 5-membered γlactam ring (a derivative of glutamine) in P1 position, which causes ten-fold increase in potency of the inhibitors. Synthetic efforts were, therefore, aimed at optimizing the substituents at the P1′, P2, and P3 positions of the α-ketoamides. In silico studies between inhibitor 289s and 3CLpro revealed the interaction of cyclopropane of S1 site with amino acid residues such as: Gln189, Arg188, Asp187, Met49, and Met165 (Figure 8 ) 40 . 9b, 14a, 38c, 53, 69, 83a, cinanserin, 108a, 113c, 137,149a, 162b, 172a, 180a, 204 214o, 226d, 247, 256 and 289s) . The chemical synthesis of SMIs under isatin derivatives 41 Chloropyridyl ester is a class of heteroaromatic organic molecule that was used They have also incorporated substituted phenyl sulphonyl group to the indole by direct sulfonamidation reaction but it has been found that the sulphonylindole Chloropyridyl products were not active in the anti-viral activity 42 . The binding interaction of compound 294a obtained by Gold dock with the enzyme as observed in the in silico study showed that the carbonyl group in the S2 site interacted with Gly143, Ser144, Cys145, the nitrogen of the chloropyridinyl in the S1 site is in close proximity with His163 residue of the macromolecule (Figure 9 ) 42 . A major class of heterocyclic compounds that exist in many drugs and synthetic products are pyrazolone derivatives 91 The computational studies of compound 300c showed that the phenyl ring of the S1 site interacted with Met-49, Arg-188, and Gln-189; the 4-carboxy benzyl of the S2 site interacted with Gln-192 residues of protease as detected in Figure 9 43 . In 2010, Ramajayam and co-workers developed a series of 2-(benzylthio)-6oxo-4-phenyl-1,6-dihydropyrimidine derivatives as SARS-CoV 3CLpro inhibitors. They have been identified various heterocycles as a novel anti-SARS agent against SARS-CoV 3CLpro from high throughput screening. They have designed the compounds from the data of complete pharmacophore modelling, and synthesized some potential pyrimidine derivatives in two steps ( Scheme 23) and tested in vitro against SARS-CoV 3CLpro, by using previously reported fluorescence assay. The biological evaluation data have reported some potent inhibitors against SARS-CoV 3CLpro, and compound 306c is one of them with IC 50 value 6.1 ± 1.1 µM (Figure 9 ) 44 . The pyrimidine derivatives 306a-n has been synthesized via two steps. The reaction started with substituted benzaldehyde 301, ethyl cyanoacetate 302, and thiourea 303; all three compounds have reacted and converted into compounds 306a-n 100 . In the next step, the compounds 304a-n were transferred to the target pyrimidine derivatives 306a-n by reacting with various halides 305 under appropriate reaction conditions ( In compound 306c, the para-nitro benzyl group of S1 site interacted with Gly-143 and Cys-145; the 4-chloro of the phenyl ring of S2 site interacted with Met-49 and Gln-189 amino acid residues of protease as detected in the in silico study (Figure 9 ) 44 . Macrocycle is a large ring-shaped cyclic molecule with exciting features to interact with the intracellular proteins and were used as a potential drug candidate for many pharmacologically important targets through the inhibition of intracellular protein-protein complexes. Several compatible strategies were already developed over the past decade to synthesize and screen the macrocycle libraries for binding to pharmacologically important targets. Due to its important chemical features, such as higher affinity, higher metabolic stability, better membrane permeability, and selectivity towards proteins, macrocyclic inhibitors have attracted considerable attention to researchers in drug discovery. The substitution of a carboxamide group with a series of substituted sulfonamide moieties have been explored by Liu and co-workers in 2014 to enhance the inhibitory effect towards SARS-CoV 3CLpro 46 The S1 site composed of the piperidine and the sulfonyl moiety was observed to fit in the hydrophobic pocket formed by Met49, Met165, Gln189, Arg188 residues, and the S2, which is in close proximity with the Cys145. The benzyl group present in S3 is near Phe140, Glu166, Leu141 residues. The two ketone groups and the nitrogen in S4 were also found to interact with Gly143, Asn142, Ser144 residues of the 3CLpro (Figure 9 ) 46 . Kumar The biological activity showed that molecules have low micromolar inhibitory activity and could inhibit NA and 3CLpro enzymes as a dual target antiviral agent. Among all pyrazolone compounds, 337a has shown the best inhibitory activity against the SARS-CoV 3CLpro with IC 50 = 5.8 ± 1.5 μM (Figure 9 ) 47 . The substituted furfural aldehyde fragment 332 has been synthesized by using published literature methods 112 The S1 site composed of the chlorobenzoic acid moiety was observed to interact with Gly143, His163, Ser144, and Cys145 residues and the trimethyl group of S2 fit in the hydrophobic pocket formed by Met49 and Gln189. The carbonyl group of pyrazolone derivative present in the S3 was found to interact with the His41 residue of the 3CLpro (Figure 9 ) 47 . Konno Results obtained from in silico study of compound 348 showed that the carbonyl group in the S1 site and amino group in S2 interacted with Cys145 and Gln189 amino acid residues of the enzyme, respectively (Figure 9 ) 48 . Hiroyuki Konno, has designed and synthesized phenylisoserine derivatives from reported molecule tetrapeptide aldehyde (IC 50 = 98 mm) and SK23 (IC 50 = 30mm) for SARS-CoV 3CLpro inhibition by the combination of SAR and docking simulation study. The molecular design of phenylisoserine derivatives has been started using three steps: serine to isoserine backbone, induction of the functionality at the P2 position, and SAR study. The inhibitory activity has been determined using a synthetic decapeptide as a substrate against SARS 3CL The binding interaction of compound 356 with the protease revealed the interaction of the ester group in S1 site of the compound with the amino acid residues Gln189, His41, Cys145 and that of keto in the S2 site interacted with His164 of the protease (Figure 9 ) 49 . Shin 291a, 294a, 300c, 306c, 316a, 328a, 337a, 348, 356, and 357b ). Computational chemistry and pharmaceutical chemistry plays a tremendous role in drug discovery and development from the last decade 113 . Nowadays, discovering lead molecules or identifying potential drug candidates for various diseases is one of the challenging scenarios for researchers. To overcome this challenge, the research groups are focusing on using pharmacoinformatic tools to minimize the time, cost, manpower, and errors for developing the potential drugs. By using the above tools, searching thousands of molecules from various databases and simultaneous identification of the best fit molecules for target protein becomes less tedious 114 . The interactive information derived between proteins (macromolecule) and ligands can help the chemist to design and synthesize the most potent inhibitors against SARS-CoV by analyzing the SAR 115, 116 . Here, we have summarized the computational chemistry aspects of SARS-CoV 3CLpro inhibitors, including the various SARS-CoV 3CL proteases (PDB IDs), types of bond between the ligands and various amino acids of the protease, frequency of amino acid residues involved in the interaction ( Table 1) . It was observed that the 11 frequent amino acid residues are mainly responsible for the interactions, which include Cys145, Glu166, Gln189, His163, Gly143, Ser144, Phe140, His41, Met49, His164, Met165 (Figure 10, 10B) . Cell-based therapies can revolutionize contribution to currently unfulfilled healthcare problems, hence making effective manufacturing critical. Before any of this could become a possibility, numerous barriers must be solved, as well as a deeper since 2003, owing to their ability to sustain viral replication to high titers, due to their higher expression of the ACE-2 receptor 118 . Translation cell-based assays for SARS-CoV had given proper insight into the mechanism of action of the potential inhibitors that are may be helpful for the drug discovery process in the near future 119, 120 . Table 3 shows the activities of cell-based assays of various inhibitors that are used in this review. Table 3 : Summary of cell-based assay for SARS-CoV 3CLpro. 3CLpro is an important drug target for SARS-CoV, as virus-encoded protease involves the processing of the two viral polyproteins and responsible for the viral replication and infection process 6 . This review deals with the chemical synthesis and medicinal chemistry perspectives of PIs and SMIs targeting SARS-CoV 3CLpro, which has been chemically synthesized and biologically screened as newer derivatives from 2004-2020 for therapeutic inventions of SARS-CoV. In this overview, we have also identified the 291a, 294a, 300c, 306c, 316a, 328a, 337a, 348, 356, and 357b . From the computational chemistry and protein interaction information's data of SARS-CoV 3CLpro inhibitors, it may be suggested that peptidomimetics (covalent and non-covalent inhibitors) and SMIs exhibited specific and effective active-site inhibition. The protein-drug interaction of inhibitors 14a, 38c, 69, 83a, 108a, 113c, 137, 149a, 172a, 180a, 204, 214o, 256, 289s, 291a, 294a, 300c, 306c, 328a, 337a, 348 , and 356 has been also analyzed with different PDB IDs, except inhibitors 53, 162b, 226d, 247, 316a, and 357b ( Table 1) . 3CLpro inhibitors have been extensively studied, enabling the production of a percentage frequency graph that displays the most critical amino acid residues detected for interaction with the ligands. From this, it was verified that these compounds interact step (a) was the coupling of peptides by using N,N0-dicyclohexylcarbodiimide and N-hydroxysuccinimide. Step (b) was the coupling of peptides by the mixed anhydride method. Step (c) was the deprotection of benzyl carbamates by using palladium on charcoal. Step (d) was the deprotection of Boc, Trt, Pbf groups and tertiary butyl esters by using TFA. Step (e) was the transformation of primary amide to nitrile by using trifluoroacetic anhydride. (1) Conditions A, B or C, DIPEA, CH 2 Cl 2 , rt. (2) 50% TFA/CH 2 Cl 2 , rt. 3) Cl -P + Ph3CH2OMe 73% ( Table 3  Synthetic pathways of PIs and SMIs are discussed in this review.  Computational chemistry including protein-ligand interactions are also highlighted. Chloropyridiyl ester derivatives 6.9 ± 0.9 Vero E6 Newly discovered coronavirus as the primary cause of severe acute respiratory syndrome History and Recent Advances in Coronavirus Discovery Characterization of a novel coronavirus associated with severe acute respiratory syndrome Unique and conserved features of genome and proteome of SARS-coronavirus, an early split-off from the coronavirus group 2 lineage Drug Development and Medicinal Chemistry Efforts toward SARS-Coronavirus and Covid-19 Therapeutics An overview of severe acute respiratory syndrome-coronavirus (SARS-CoV) 3CL protease inhibitors: Peptidomimetics and small molecule chemotherapy A review of studies on animal reservoirs of the SARS coronavirus Chemistry and Biology of SARS-CoV-2 Rapid Risk Assessment: Severe Respiratory Disease Associated with Middle East Respiratory Syndrome Coronavirus (MERS-CoV), 20th Update A new coronavirus associated with human respiratory disease in China World Health Organizations, Emergencies, Diseases. Coronavirus disease (COVID-19 Considerations for the discovery and development of 3-chymotrypsin-like cysteine protease inhibitors targeting SARS-CoV-2 infection Targeting SARS-CoV-2 Proteases and Polymerase for COVID-19 Treatment: State of the Art and Future Opportunities Discovery of Ketone-Based Covalent Inhibitors of Coronavirus 3CL Proteases for the Potential Therapeutic Treatment of COVID-19 ALG-097111, a potent and selective SARS-CoV-2 3-chymotrypsin-like cysteine protease inhibitor exhibits in vivo efficacy in a Syrian Hamster model Fight against novel coronavirus: A perspective of medicinal chemists Druggable targets from coronaviruses for designing new antiviral drugs Repurposing therapeutics for COVID-19: Rapid prediction of commercially available drugs through machine learning and docking Pharmacoinformatics and molecular dynamics simulation studies reveal potential covalent and FDA-approved inhibitors of SARS-CoV-2 main protease 3CLpro Identification of Nafamostat and VR23 as COVID-19 drug candidates by targeting 3CLpro and PLpro Organic synthesis provides opportunities to transform drug discovery The importance of synthetic chemistry in the pharmaceutical industry Synthesis and evaluation of keto-glutamine analogues as potent inhibitors of severe acute respiratory syndrome 3CLpro Discovery of potent anilide inhibitors against the severe acute respiratory syndrome 3CL protease Inhibition of the severe acute respiratory syndrome 3CL protease by peptidomimetic α,β-unsaturated esters Synthesis of glutamic acid and glutamine peptides possessing a trifluoromethyl ketone group as SARS-CoV 3CL protease inhibitors Synthesis, crystal structure, structure-activity relationships, and antiviral activity of a potent SARS coronavirus 3CL protease inhibitor Design, synthesis, and evaluation of inhibitors for severe acute respiratory syndrome 3C-like protease based on phthalhydrazide ketones or heteroaromatic esters Design and synthesis of cinanserin analogs as severe acute respiratory syndrome coronavirus 3CL protease inhibitors Design, synthesis, and evaluation of trifluoromethyl ketones as inhibitors of SARS-CoV 3CL protease New developments for the design, synthesis and biological evaluation of potent SARS-CoV 3CLpro inhibitors Structure-based design, synthesis, and evaluation of peptide-mimetic SARS 3CL protease inhibitors Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors Development of potent dipeptide-type SARS-CoV 3CL protease inhibitors with novel P3 scaffolds: Design, synthesis, biological evaluation, and docking studies Design, synthesis, and biological evaluation of novel dipeptide-type SARS-CoV 3CL protease inhibitors: Structureactivity relationship study Design, synthesis and crystallographic analysis of nitrile-based broad-spectrum peptidomimetic inhibitors for coronavirus 3C-like proteases Design and synthesis of new tripeptidetype SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety Identification and evaluation of potent Middle East respiratory syndrome coronavirus (MERS-CoV) 3CLPro inhibitors Evaluation of a non-prime site substituent and warheads combined with a decahydroisoquinolin scaffold as a SARS 3CL protease inhibitor α-Ketoamides as Broad-Spectrum Inhibitors of Coronavirus and Enterovirus Replication: Structure-Based Design, Synthesis, and Activity Assessment Synthesis and evaluation of isatin derivatives as effective SARS coronavirus 3CL protease inhibitors Design, synthesis and antiviral efficacy of a series of potent chloropyridyl ester-derived SARS-CoV 3CLpro inhibitors Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors Synthesis, docking studies, and evaluation of pyrimidines as inhibitors of SARS-CoV 3CL protease Macrocyclic inhibitors of 3C and 3C-like proteases of picornavirus, norovirus, and coronavirus Synthesis, modification and docking studies of 5-sulfonyl isatin derivatives as SARS-CoV 3C-like protease inhibitors Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors Design and synthesis of a series of serine derivatives as small molecule inhibitors of the SARS coronavirus 3CL protease Synthesis and evaluation of phenylisoserine derivatives for the SARS-CoV 3CL protease inhibitor Evaluation of an octahydroisochromene scaffold used as a novel SARS 3CL protease inhibitor The genome sequence of the SARS-associated coronavirus Coronavirus genome structure and replication The Molecular Biology of Coronaviruses Virus entry: Molecular mechanisms and biomedical applications Coronavirus spike proteins in viral entry and pathogenesis The coronavirus replicase Homology Models of Coronavirus 2019-NCoV 3CLpro Protease The crystal structures of severe acute respiratory syndrome virus main protease and its complex with an inhibitor Severe acute respiratory syndrome coronavirus papain-like-protease: Structure of a viral deubiquitinating enzyme Targeting protein-protein interactions as an anticancer strategy Design of nonpeptides from peptide ligands for peptide receptors Conformationally Constrained Amino Acids and Peptides in the Design of Bioactive Polypeptide Ligands Clinical overview of MDM2/X-targeted therapies Intracoronary KAI-9803 as an adjunct to primary percutaneous coronary intervention for acute ST-segment elevation myocardial infarction Synthesis and evaluation of keto-glutamine analogues as inhibitors of hepatitis A virus 3C proteinase Severe acute respiratory syndrome coronavirus (SARS-CoV) infection inhibition using spike protein heptad repeat-derived peptides Structural variations in keto-glutamines for improved inhibition against hepatitis A virus 3C proteinase An efficient synthesis of a key intermediate for the preparation of the rhinovirus protease inhibitor AG7088 via asymmetric dianionic cyanomethylation of N-Boc-L-(+)-glutamic acid dimethyl ester Evaluation of metal-conjugated compounds as inhibitors of 3CL protease of SARS-CoV Rapid diversity-oriented synthesis in microtiter plates for in situ screening: Discovery of potent and selective α-fucosidase inhibitors Characterization of SARS main protease and inhibitor assay using a fluorogenic substrate Viral proteinases Structure-based design, synthesis, and biological evaluation of irreversible human rhinovirus 3C protease inhibitors. 4. Incorporation of P1 lactam moieties as L-glutamine replacements Inactivation of serine protease, α-chymotrypsin by fluorinated phenylalanine analogues Biosynthesis of 4-methylproline in cyanobacteria: Cloning of nosE and nosF genes and biochemical characterization of the encoded dehydrogenase and reductase activities Amino acids and peptides; 60.1 synthesis of biologically active cyclopeptides Highly diastereoselective peptide chain extensions of unprotected amino acids with N-(Z-α-aminoacyl)benzotriazoles. Synthesis (Stuttg) In vitro antiviral activity of AG7088, a potent inhibitor of human rhinovirus 3C protease High-throughput screening identifies inhibitors of the SARS coronavirus main proteinase Cinanserin Is an Inhibitor of the 3C-Like Proteinase of Severe Acute Respiratory Syndrome Coronavirus and Strongly Reduces Virus Replication In Vitro Design and synthesis of dipeptidyl glutaminyl fluoromethyl ketones as potent severe acute respiratory syndrome coronovirus (SARS-CoV) inhibitors A convergent synthesis of 4-(2-benzothiazoyl)piperidines with antihistamic activity Reactifs de couplage peptidique I (1) -l'hexafluorophosphate de benzotriazolyl N-oxytrisdimethylamino phosphonium Improved solid phase synthesis of C-terminal peptide aldehydes Characterization and inhibition of norovirus proteases of genogroups I and II using a fluorescence resonance energy transfer assay Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line Tripeptide aldehyde inhibitors of human rhinovirus 3C protease: Design, synthesis, biological evaluation, and cocrystal structure solution of P1 glutamine isosteric replacements Design and synthesis of new tripeptidetype SARS-CoV 3CL protease inhibitors containing an electrophilic arylketone moiety Design, synthesis, and evaluation of 3C protease inhibitors as anti-enterovirus 71 agents Stable Benzotriazole Esters as Mechanism-Based Inactivators of the Severe Acute Respiratory Syndrome 3CL Protease Pyrazolone structural motif in medicinal chemistry: Retrospect and prospect Pyrazolone derivatives: Synthesis, anti-inflammatory, analgesic quantitative structure-activity relationship and in vitro studies Synthesis, and Characterization of Some Hybridized Pyrazolone Pharmacophore Analogs against Mycobacterium tuberculosis Abu Abed OS. Synthesis of new pyrazolone and pyrazole-based adamantyl chalcones and antimicrobial activity Synthesis and biological evaluation of pyrazolone analogues as potential anti-inflammatory agents targeting cyclooxygenases and 5-lipoxygenase Investigation of antioxidant and anti-nociceptive potential of isoxazolone, pyrazolone derivatives, and their molecular docking studies Discovery of pyrazolone spirocyclohexadienone derivatives with potent antitumor activity Cross-coupling of 1-aryl-5-bromopyrazoles: Regioselective synthesis of 3,5-disubstituted 1-arylpyrazoles Studies on 1,3-diaryl pyrazolones and their derivatives 5-Cyano-6-aryluracil and 2-thiouracil derivatives as potential chemotherapeutic agents. IV Click Chemistry for Drug Discovery Accessing skeletal diversity using catalyst control: Formation of n and n + 1 macrocyclic triazole rings New β-strand templates constrained by Huisgen cycloaddition Cu(I)-and Ru(II)-mediated "click" cyclization of tripeptides toward vancomycin-inspired mimics Potent inhibition of norovirus 3CL protease by peptidyl α-ketoamides and α-ketoheterocycles Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors Synthesis and biological evaluation of quinoline salicylic acids as P-selectin antagonists Isatin 1,2,3-triazoles as potent inhibitors against caspase-3 Potent and selective nonpeptide inhibitors of caspases 3 and 7 Identification, synthesis, and evaluation of new neuraminidase inhibitors Synthesis and evaluation of pyrazolone compounds as SARS-coronavirus 3C-like protease inhibitors Synthesis of new cyano-substituted bis-benzothiazolyl arylfurans and arylthiophenes Computational Chemistry in the Pharmaceutical Industry: From Childhood to Adolescence The impact of in silico screening in the discovery of novel and safer drug candidates Machine learning in chemoinformatics and drug discovery Chemoinformatics and drug discovery Coronavirus main proteinase (3CLpro) Structure: Basis for design of anti-SARS drugs SARS-coronavirus-2 replication in Vero E6 cells: Replication kinetics, rapid adaptation and cytopathology SARS coronavirus induces apoptosis in Vero E6 cells The life cycle of SARS coronavirus in Vero E6 Synthesis of CF 3 -ketone containing glutamic acid and glutamine peptides. Scheme 4, 4A: Synthesis of intermediate 45 (trifluoromethyl-b-amino alcohol) 4B: Synthesis of intermediate 48 (glutamic acid and glutamine peptides with a CF 3 -ketone unit) 83 Scheme 5: Synthesis of inhibitor TG-0205221 (69) 6D: Synthesis of a series of 3-Chloropyridinyl Esters by Method A or B Scheme 6, 6E: Synthesis of 3-Chloro-5-furan-(2-ylmethoxy)pyridine (85) Scheme 6, 6F: Synthesis of Furan-2-yl Nicotinate Scheme 6, 6G: Synthesis of and N-(Pyridin-3-yl)thiophene-2-sulfonamide 6H: Synthesis of 2-(Pyridin-3-yl)-1-(thiophen-2-yl)ethanone (92) Scheme 6, 6I: Synthesis of 2-(5-Bromopyridin-3-yl)-1-(furan-2-yl)ethanone Scheme 6, 6K: Synthesis of Synthesis of a cinanserin analogues (Series I, Series II, and Series III) Synthesis of trifluoromethyl, benzothiazolyl or thiazolyl ketone containing peptidomimetic inhibitors 15A: synthesis of dipeptidic key fragment 209; Scheme 15, 15B: synthesis of tripeptide inhibitor 214a-u, 215a-d, and 216a-i; and Scheme 15, 15C: synthesis of tripeptide inhibitor-containing imidazole moiety 221a-c 19A: synthesis of key lactam fragment 279; Scheme 19, 19B: synthesis of amino acids intermediates 283a-u, and Scheme 19, 19C: synthesis of α-Ketoamides derivatives 289a-u by addition of two intermediates 279 and 283a-u 26A: synthesis of substituted furfural aldehyde fragment 332; Scheme 26, 26B: synthesis a series of pyrazolones derivatives 337a-s; Scheme 26, 26C: synthesis of compound 340; and Scheme 26, 26D: synthesis of compound 344 Abhik Paul is thankful to the All-India Council for Technical Education (AICTE), New Delhi, India for awarding a fellowship (AICTE-NDF). Arnab Sarkar, Sanjukta Saha and Pritha Janah are thankful to the All-India Council for Technical Education (AICTE), New Delhi, India for awarding the fellowship. Avik Maji is thankful to RUSA 2.0 of University Grants Commission (UGC), New Delhi for awarding a fellowship. The authors heartily thank Mind the GRAPH (Senior plan) for providing graphical illustrations, and https://www.rcsb.org/ for providing 3D structures of macromolecules. The authors also thank the support from the Department of Pharmaceutical Technology, Jadavpur University, Kolkata for providing research amenities.